HAVCR2 and neoplasm: Furthermore, TIGIT, LAG-3, HAVCR2 (TIM-3), and IDO1 are known as novel immune checkpoint targets that can suppress the activation of effector T lymphocytes, hence mediating a tumor immune escape mechanism [32, 36, 37].